Monthly Archives: December 2011

The 'S' Word in Healthcare Reform

by Tom Norton In little more than two years, the main elements of the HCR will take hold across the nation.  As implementation continues to ramp up, one of the more intriguing questions surrounding its activation is, is the “S” word being realized?…That is, “S” as in “savings.” Are the much publicized “savings” that were […]
Posted in Guest Blog, healthcare, Regulatory, Strategy | Tagged , , , , , | 3 Comments

Call for Ad Stars Submissions!

Call for Ad Stars Submissions! It’s that time again for the editors of Pharm Exec to narrow down its choices for our annual Ad Stars feature, recognizing the most clever, unique and effective campaigns in pharma advertising over the past year.
Posted in Strategy | Leave a comment

Putting the M Back in M&A

Joe Panetta, president and CEO of BIOCOM, discusses an emerging model of M&As in which human and IP assets are valued and biotech brings expertise to Big Pharma as venture capitalist funding dwindles and patent cliffs loom large. Pharm Exec: Can you tell me about how small biotech and specialty companies have started switching from […]
Posted in Agency Insight, Biotech, Deals, FDA | Tagged , , , | Leave a comment

Lilly's Decentralized Global Launch Strategy

Global headquarters may get the strategic ball rolling for a new drug launch, but Lilly’s affiliates are responsible for bringing home the bacon, according to a Lilly global brand director.
Posted in Global, leadership, Market Access, Strategy | Tagged , | Leave a comment

Not Just Numbers: R&D Decline Measured in More Than NMEs

The hard (declining) numbers of approved NMEs in the past 10 to 15 years tell a powerful story. But is it the whole story?
Posted in R&D | Tagged , , | 1 Comment
  • Categories

  • Meta